TY - JOUR
T1 - Twelve-month psychosocial outcomes of continuous glucose monitoring with behavioural support in parents of young children with type 1 diabetes
AU - the Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group
AU - Commissariat, Persis V.
AU - DiMeglio, Linda A.
AU - Kanapka, Lauren G.
AU - Laffel, Lori M.
AU - Miller, Kellee M.
AU - Anderson, Barbara J.
AU - Hilliard, Marisa E.
AU - Woerner, Stephanie
AU - Harrington, Kara
AU - Anderson, Barbara J.
AU - Hilliard, Marisa E.
AU - DeSalvo, Daniel
AU - Tamborlane, William
AU - Van Name, Michelle
AU - Miller, Kellee M.
AU - Harrington, Kara
AU - Hanono, Anat
AU - Naik, Nisha
AU - Ambler-Osborn, Louise
AU - Schultz, Alan
AU - Woerner, Stephanie
AU - Jolivette, Heather
AU - Ismail, Heba
AU - Tebbe, Megan
AU - Newnum, America
AU - Legge, Megan
AU - Tamborlane, William
AU - Van Name, Michelle
AU - Weyman, Kate
AU - Finnegan, Jennifer
AU - Steffen, Amy
AU - Zgorski, Melinda
AU - DeSalvo, Daniel
AU - Hilliard, Marisa
AU - Anderson, Barbara
AU - DeLaO, Kylie
AU - Xie, Cicilyn
AU - Levy, Wendy
AU - Wadwa, R. Paul
AU - Forlenza, Greg
AU - Majidi, Shideh
AU - Alonso, Guy
AU - Weber, Isabel
AU - Clay, Michelle
AU - Simmons, Emily
AU - Nathan, Brandon
AU - Sunni, Muna
AU - Sweet, Jessica
AU - Pappenfus, Beth
AU - Kogler, Anne
N1 - Publisher Copyright:
© 2023 Diabetes UK.
PY - 2023/8
Y1 - 2023/8
N2 - Aim: Managing type 1 diabetes in young children can cause significant stress for parents. Continuous glucose monitoring (CGM) may reduce parental burden. The Strategies to Enhance CGM Use in Early Childhood (SENCE) trial randomized parents of children (ages 2 to <8 years) with type 1 diabetes to CGM with family behavioural intervention (CGM + FBI), CGM alone (Standard-CGM) or blood glucose monitoring for 26 weeks before receiving CGM + FBI (BGM-Crossover). This report assesses changes in psychosocial outcomes for all groups over 52 weeks. Methods: CGM + FBI (n = 45), Standard-CGM (n = 42) and BGM-Crossover (n = 44) participants completed psychosocial assessments at baseline, 26 weeks and 52 weeks. Repeated measures linear regression models evaluated change within and between treatment groups. Results: The BGM-Crossover group reported improved diabetes burden (Δ −6.9, 95% CI [−11.3, −2.6], p = 0.003), fear of hypoglycaemia (Δ −6.4, CI [−10.1, −2.6], p = 0.002) and technology satisfaction (Δ 7.3, CI [2.4, 12.2], p = 0.005) from 26 to 52 weeks, similar to published findings in the CGM + FBI group over the first 26 weeks. The Standard-CGM group reported increased technology satisfaction (Δ 7.3, CI [0.6, 14.0], p = 0.027) from baseline to 52 weeks. The CGM + FBI group reported less diabetes burden and fear of hypoglycaemia from baseline to 52 weeks, but changes were not statistically significant. Scores from 26 to 52 weeks did not deteriorate. Conclusions: Parents demonstrated psychosocial benefits following FBI that appeared to maintain without additional intervention. CGM-focused education with behavioural support likely helps parents of young children with type 1 diabetes reduce burden and worry in the short- and long-term.
AB - Aim: Managing type 1 diabetes in young children can cause significant stress for parents. Continuous glucose monitoring (CGM) may reduce parental burden. The Strategies to Enhance CGM Use in Early Childhood (SENCE) trial randomized parents of children (ages 2 to <8 years) with type 1 diabetes to CGM with family behavioural intervention (CGM + FBI), CGM alone (Standard-CGM) or blood glucose monitoring for 26 weeks before receiving CGM + FBI (BGM-Crossover). This report assesses changes in psychosocial outcomes for all groups over 52 weeks. Methods: CGM + FBI (n = 45), Standard-CGM (n = 42) and BGM-Crossover (n = 44) participants completed psychosocial assessments at baseline, 26 weeks and 52 weeks. Repeated measures linear regression models evaluated change within and between treatment groups. Results: The BGM-Crossover group reported improved diabetes burden (Δ −6.9, 95% CI [−11.3, −2.6], p = 0.003), fear of hypoglycaemia (Δ −6.4, CI [−10.1, −2.6], p = 0.002) and technology satisfaction (Δ 7.3, CI [2.4, 12.2], p = 0.005) from 26 to 52 weeks, similar to published findings in the CGM + FBI group over the first 26 weeks. The Standard-CGM group reported increased technology satisfaction (Δ 7.3, CI [0.6, 14.0], p = 0.027) from baseline to 52 weeks. The CGM + FBI group reported less diabetes burden and fear of hypoglycaemia from baseline to 52 weeks, but changes were not statistically significant. Scores from 26 to 52 weeks did not deteriorate. Conclusions: Parents demonstrated psychosocial benefits following FBI that appeared to maintain without additional intervention. CGM-focused education with behavioural support likely helps parents of young children with type 1 diabetes reduce burden and worry in the short- and long-term.
KW - CGM
KW - burden
KW - fear of hypoglycaemia
KW - randomized clinical trial
KW - type 1 diabetes
KW - young children
UR - http://www.scopus.com/inward/record.url?scp=85164844326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164844326&partnerID=8YFLogxK
U2 - 10.1111/dme.15120
DO - 10.1111/dme.15120
M3 - Article
C2 - 37083018
AN - SCOPUS:85164844326
SN - 0742-3071
VL - 40
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 8
M1 - e15120
ER -